Specific allergen immunotherapy for the treatment of atopic eczema (Q24186146)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

8

Robert J Boyle

Robert J

Boyle

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

7

Stephen Durham

Stephen

Durham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

2

Moises A Calderon

Moises A

Calderon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Herman Tam

1

Herman

Tam

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Helen Nankervis

series ordinal

4

author given names

Helen

author last names

Nankervis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Ignacio García Núñez

series ordinal

5

author given names

Ignacio

author last names

García Núñez

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Hywel C Williams

series ordinal

6

author given names

Hywel C

author last names

Williams

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

12 June 2020

language of work or name

1 reference

12 February 2016

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

CD008774

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26871981%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Clinical and immunological changes of immunotherapy in patients with atopic dermatitis: randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Immunotherapy at the ACAAI Annual Meeting. 6th International Congress on Autoimmunity, 9-13 September 2008, Porto, Portugal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Sublingual immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Certainties and doubts about sublingual and oral immunotherapy in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Specific immunotherapy in atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Immunotherapy for allergies and asthma: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Treatment of atopic dermatitis with a combination of allergen-specific immunotherapy and a histamine-immunoglobulin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

[Specific immunotherapy in the treatment of atopic dermatitis].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Allergen specific immunotherapy for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Investigational and Unproven Therapies in Atopic Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Recent advances in treatment strategies for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Poster 2009: Clinical substantiation of immunocorrective therapy in children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

When to initiate immunotherapy in children with allergic disease? Lessons from the paediatric studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Randomized controlled trial of primary prevention of atopy using house dust mite allergen oral immunotherapy in early childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Injection allergen immunotherapy for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

The pathophysiology of atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Operating characteristics of a rank correlation test for publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Venom immunotherapy for preventing allergic reactions to insect stings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Allergen injection immunotherapy for seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Specific allergen immunotherapy for the treatment of atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Sublingual immunotherapy for treating allergic conjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Environmental prevention in atopic eczema dermatitis syndrome (AEDS) and asthma: avoidance of indoor allergens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Allergen-specific immunotherapy for atopic eczema: updated

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Long-term clinical efficacy of grass-pollen immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective follow-up to 7 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

The natural course of atopic dermatitis from birth to age 7 years and the association with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Efficacy of allergen-specific immunotherapy for patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

How epidemiology has challenged 3 prevailing concepts about atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Safety of sublingual immunotherapy started during the pollen season

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Immunotherapy – 2082. Long term prevention of asthma and rhinitis in children with atopic dermatitis four year after discontinuation of sublingual immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

Early treatment of the atopic child: first results of the clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

[Specific immunotherapy (SIT) in atopic dermatitis and food allergy]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren☆☆☆★

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

[Value of Allerglobulin in the treatment of atopic dermatitis in children and young adults. A double-blind randomized study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

FcIgG receptor-bearing lymphocytes and monoclonal antibody-defined T cell subsets in atopic dermatitis: effect of treatment with thymopoietin pentapeptide (TP-5)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Oral hyposensitization to nickel allergy: preliminary clinical results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Immunotherapy of atopic dermatitis by injections of antigen-antibody complexes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

A clinical trial of oral hyposensitization in systemic allergy to nickel

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Allergy to nickel: first results on patients administered with an oral hyposensitization therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

Effects of oral bacterial immunotherapy in children with atopic eczema/dermatitis syndrome : a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021

New applications for sublingual immunotherapy in allergy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008774.PUB2

7 January 2021